Overview

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
Phase:
Phase 1
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Treatments:
Trastuzumab